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Introduction: Intermittent oral delivery of levodopa is a major contributing factor for motor complica-
tions in Parkinson's disease (PD). Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) into the
jejunum using a portable pump via percutaneous endoscopic gastrostomy (PEG) improves motor com-
plications and quality of life (QoL).
Objectives: To record long-term effectiveness of advanced PD patients undergoing LCIG infusion in
routine care, by Uniﬁed Parkinson's Disease Rating Scale (UPDRS), Non-Motor Symptoms Scale (NMSS),
PDQ-8 and EQ-5D questionnaires.
Methods: Overall, 375 patients from 75 movement disorder centers in 18 countries were enrolled in this
prospective non-interventional study. The 12-month interim outcomes of the ﬁrst 172 included patients
are presented here.
Results: There were reductions of mean daily “Off” time from baseline (BL) (7.1 ± 3.5 h) and “On” time
with dyskinesias (5.2 ± 4.5 h) at month 12 (M12) of 4.7 ± 3.4 and 1.7 ± 5.0 h respectively (p < 0.0001;
p ¼ 0.0228). UPDRS II and III “On” scores decreased from BL to M12 (p ¼ 0.0107 and p ¼ 0.0128). Total
NMSS and PDQ-8 scores improved at M12 (p ¼ 0.0014 and p ¼ 0.0100). Mean LCIG dose administered
through PEG at ﬁrst visit (day after implantation) was 1304 ± 618 mg/day and remained stable through
M12. Continuous LCIG infusion tolerability and adverse drug reactions were consistent with the known
safety proﬁle of previous studies.
Conclusions: This observational, routine-care study supports long-term safety and efﬁcacy of LCIG
infusion in advanced PD including motor, non-motor and QoL improvements.
© 2015 AbbVie Inc. employs authors Yegin, Preda, and Bergmann. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).isorders Unit, IRCCS Hospital
(02) 57993319.
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Table 1
Baseline patient demographics and disease characteristics.
Demographics
Gender
Female 96 (55.8%)
Male 76 (44.2%)
Age (years) 66.5 ± 9.3
<65 years 60 (35.0%)
65 years 112 (65.0%)
Medical history
Time since PD diagnosis (years) 12.6 ± 6.6
Hoehn and Yahr 2.8 ± 0.8
Dementia 20 (11.7%)
Impulse control disorder 26 (15.2%)
PD symptoms and QoL measures at baseline
“Off” time (UPDRS item 39) hours/day 7.1 ± 3.5
Time with dyskinesia (UPDRS item 32) hours/day 5.2 ± 4.5
UPDRS II (activities of daily living) at “On” state 16.5 ± 10.7
UPDRS III (motor examination) at “On” state 26.5 ± 12.3
Non-Motor Symptoms Scale (NMSS total score) 75.3 ± 42.2
Quality of life (PDQ-8 total score) 48.6 ± 19.0
Previous PD medication as reported at baseline
Levodopa n (97.1%)
Total daily dose (mg) 884 ± 444
Dopamine agonist n (64.5%)
COMT inhibitors n (55.8%)
MAO-B inhibitors n (33.1%)
Amantadine n (22.7%)
Other oral medications n (16.9%)
Data presented in mean ± standard deviation (SD) or number (%).
Parkinson's disease (PD), Uniﬁed Parkinson's Disease Rating Scale (UPDRS), Non-
Motor Symptoms Scale (NMSS), Parkinson's Disease Questionnaire e 8 item (PDQ-
8), Catechol O-methyl transferase (COMT), Monoamine oxidase-B (MAO-B).
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Parkinson's disease (PD) is a progressive neurodegenerative
disorder with a high worldwide prevalence [1]. Levodopa, a
dopamine precursor, is the most effective symptomatic therapy
for the cardinal motor features of PD [2] but complications such as
motor and non-motor response ﬂuctuations and abnormal
involuntary movements (dyskinesias) progressively develop in
the majority of patients, becoming a major source of disability,
substantially interfering with daily activities and social in-
teractions, and impacting quality of life (QoL) [3e5]. Pharmaco-
logical strategies to treat motor ﬂuctuations include
fragmentation of levodopa doses, combination with catechol O-
methyl transferase (COMT) and monoamine oxidase B (MAO-B)
inhibitors or dopamine agonists (DA); amantadine has also shown
some efﬁcacy on levodopa-induced dyskinesias [6]. Patients
failing these approaches may be considered for deep brain surgery
(DBS), but continuous drug delivery via infusion therapies is a ﬁrst
line option for those with contraindications or unwillingness to
undergo brain surgery.
Levodopa-carbidopa intestinal gel (LCIG) is a stable gel sus-
pension of levodopa/carbidopa (4:1 ratio; 20/5 mg/mL) suitable for
continuous delivery in advanced PD patients via portable pump
into the duodenum through a percutaneous endoscopic gastro-
stomy (PEG) with a duodenal extension tube. Treatment with LCIG
infusion has been shown to reduce motor ﬂuctuations and dyski-
nesia in randomized controlled trials [7e9] and several open-label
series [10e21].
To date, there are only a few studies conducted in large patient
populations over extended follow-up periods. The aim of the cur-
rent study is to collect clinical outcomes in a large multicenter and
multinational cohort of patients with advanced PD receiving LCIG
in routine clinical care and to evaluate effects on motor and non-
motor symptoms and their impact on QoL over 24 months. Here
we present 12-month interim results.2. Patients and methods
The study was conducted at movement disorder centers (MDCs) in 18 countries
(Australia, Austria, Belgium, Bulgaria, Czech Republic, Denmark, France, Germany,
Greece, Ireland, Italy, Netherlands, Norway, Romania, Slovenia, Spain, Switzerland
and United Kingdom). The ﬁrst patient was enrolled in June 2010, and through June
2013, a total of 375 patients were included at 75 participating specialized MDCs. All
patients who were enrolled since start of the study up through November 2012
(n ¼ 172) were included in this 12-month interim analysis.
Male and female patients with advanced PD and motor complications eligible
for LCIG treatment according to European Commission Summary Product Charac-
teristics and to national reimbursement criteria were enrolled in this observational
study. Treatment with LCIG, consisting of a water-based suspension containing
micronized levodopa (20 mg/mL) and carbidopa (5 mg/mL) in methylcellulose
(Duodopa®), was administered by continuous duodenal infusion over 16 h using a
portable pump (CADD-Legacy); treatment was initiated in participating MDCs ac-
cording to the standard clinical procedures in routine patient care. In 2010when this
study was launched, commercial LCIG treatment was required to be initiated with a
temporary nasoduodenal tube for a recommended duration of approximately 7e14
days to verify drug efﬁcacy and optimize dose and was then continued long-term by
a PEG tube. Continuing use of other PD drugs as concomitant treatment to LCIG
infusion was allowed in this study at the discretion of the treating physician.
The following efﬁcacy and safety outcomes were assessed: Uniﬁed Parkinson's
Disease Rating Scale (UPDRS) parts II, III, IV, and V. Complications of therapy (UPDRS
IV: Items 32 and 39 were applied according to the Movement Disorder Society
(MDS)-UPDRS to allow for calculation of actual hours of “Off” time and “On” time
with dyskinesias, items 33 and 34 (dyskinesia severity and painful dyskinesias) were
severity coded (0e4) and item 35 reﬂected the proportion of patients with early
morning dystonia), activities of daily living (UPDRS II), motor performance (UPDRS
III), both assessed at the “On” state. Non-motor symptoms were assessed using the
Non-Motor Symptom Scale (NMSS), and patient reported QoL using disease-speciﬁc
Parkinson's Disease Questionnaire short version with 8 items (PDQ-8) and generic
EuroQoLe 5 Dimensions quality of life instrument (EQ-5D) questionnaires. To assess
safety of LCIG infusion, all adverse drug reactions (ADR) were recorded during both
temporal nasoduodenal tube and permanent PEG tube infusion. ADR were deﬁnedas adverse events reported by the investigator as “unlikely,” “possibly,” or “probably”
related to the study drug system.
Data were recorded at baseline (BL) prior to initiation of LCIG, at day 1 (D1) of
continuous LCIG infusion via PEG (deﬁned as the ﬁrst assessment after a run-in
period with temporary nasoduodenal administration), and at follow-up visits 6
(M6) and 12 months (M12) thereafter.
UPDRS II, III, IV and V, and NMSS data were summarized with descriptive sta-
tistics. QoL data were analyzed according the validated standard procedures deﬁned
for the two questionnaires (PDQ-8 and EQ-5D). Paired t-tests and ANOVA onmatched
pairs over timewere used for statistical testing of efﬁcacy and QoL data comparing BL
with D1, M6, and M12. ADRs were MedDRA-coded and summarized on a per-subject
basis. Out of the 172 enrolled patients as of November 2012, efﬁcacy data was
analyzed for all patients with at least one follow-up visit (n ¼ 148). All patients who
received any infusion of LCIG (either via temporal nasoduodenal tube or with sub-
sequent long-term PEG were included in the safety analysis population (n ¼ 159)).
The protocol, patient information and informed consent were approved in all
countries by national and/or local independent ethics committees and health au-
thorities according to the applicable national regulatory requirements.3. Results
Demographics, medical history, and PD characteristics of the 172
enrolled patients are summarized in Table 1. The mean age was
66.5 ± 9.3 years, and mean duration of PD was 12.6 ± 6.6 years.
Baseline assessments of motor and non-motor symptoms and
patient-reported QoL are presented in Table 1.
The mean ± standard deviation (SD) dose of orally-administered
levodopa at BL was 884 ± 444 mg/day and a majority of patients
was on one or more additional antiparkinsonian drugs, mainly
COMT inhibitors and DAs (Table 1). At the start of LCIG, approxi-
mately half of the patients were using oral levodopa, and approx-
imately 40% were using other anti-PD medications; these
proportions decreased to approximately 25% for both oral levodopa
and other anti-PD medications at M12. Primary reasons to start
LCIG treatment were disabling “Off” periods and dyskinesias, pre-
sent in 94.8% and 62.8% of patients, respectively. The median
duration of infusion per day was 16 h at D1. The mean ± SD total
daily LCIG dose was 1304 ± 62 mg/day at D1 and remained
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(1412 ± 650 mg/day). An additional morning dose was adminis-
tered in 93.1% of patients, and extra boli were administered in all
patients, with a mean ± SD of 1.7 ± 1.3 boli/day (41.2 ± 20.9 mg/
bolus). At M12 the proportion of patients with a morning dose or
extra boluses declined to 73.0% and 77.4%, respectively, while the
frequency and doses of the administered boli remained similar
(2.0 ± 1.4 boli/day; 42.6 ± 22.5 mg/boli).
Out of the 172 patients, 24 (14.4%) discontinued LCIG prema-
turely: 8 (4.7%) during the run-in period (LCIG infusion via naso-
duodenal tube), 14 (8.1%) by M6, and a further 2 (1.2%) by M12.
Reasons for premature discontinuation included adverse events
(ADRs, concomitant diseases, or death; n ¼ 15, 8.7%), withdrawal of
consent (n ¼ 5, 2.9%), and lack of efﬁcacy (n ¼ 4, 2.3%). A total of 33
patients (19.2%) did not return after inclusion to one of the follow-
up visits: 5 (2.9%) at D1, 13 (7.6%) at M6 and 15 (8.7%) at M12, and
were considered as “lost to follow-up.” Thus, of the 172 patients
enrolled, 57 were no longer included in the study, including 24who
discontinued prematurely and 33 lost to follow-up.
The mean ± SD daily hours spent in the “Off” state (UPDRS IV
item 39) signiﬁcantly decreased at D1, M6, and M12 with a
maximum reduction of 4.7 ± 3.4 h at M12 (p < 0.0001, Fig. 1A).
Mean ± SD daily hours of “On” time with dyskinesias (UPDRS IV
item 32) signiﬁcantly decreased at M6 and M12 by 1.7 ± 5.5 and
1.7 ± 5.0 h (p ¼ 0.0155 and p ¼ 0.0228, respectively). The mean
UPDRS item 33 (dyskinesia severity) was reduced from 1.7 ± 1.2 at
BL to 0.9 ± 1.2 (p < 0.0001) at M12, and UPDRS item 34 (painful
dyskinesias) from 0.8 ± 1.1 at BL to 0.6 ± 1.2 (p ¼ 0.0004) at M12.Fig. 1. Mean change from baseline at D1, M6, and M12 of LCIG treatment via PEG tube
in A) hours of “Off” time and “On” time with dyskinesias as measured by UPDRS Part
IV; B) UPDRS II and UPDRS III scores. Bars are standard deviation. Asterisks represent
statistical signiﬁcance (p  0.05) compared to baseline from paired t-test. Uniﬁed
Parkinson's Disease Rating Scale (UPDRS).The proportion of patients experiencing early morning dystonia
(UPDRS item 35) was 50.5% at BL and decreased at M12 to 24.0%
(p ¼ 0.0035). UPDRS II activities of daily living “On” scores
(mean ± SD) were reduced at M12 by 3.1 ± 8.7 points (p ¼ 0.0107),
respectively, and UPDRS III motor examination “On” scores
(mean ± SD) were reduced at M12 by 3.3 ± 11.0 points (p ¼ 0.0128)
(Fig. 1B).
NMSS total scores (mean ± SD) signiﬁcantly decreased at M6
and M12 (p ¼ 0.0001 and p ¼ 0.0014) with a maximum reduction
of 22.2 ± 50.6 points at M12 (Fig. 2A). In addition, signiﬁcant
improvements of non-motor symptoms were observed up to M12
in 3 out of the 9 NMSS domains: domain 2 (sleep/
fatigue: 7.5 ± 13.1, p ¼ 0.0001), domain 6 (gastrointestinal
tract: 2.6 ± 7.1, p ¼ 0.0096) and domain 7 (urinary: 2.8 ± 8.7,
p ¼ 0.0199) while signiﬁcant improvements in domain 3 (mood/
cognition: 4.1 ± 16.7, p ¼ 0.0426) was evident only at M6.
PDQ-8 scores (mean ± SD) signiﬁcantly improved at each
follow-up with a maximum reduction of 8.6 ± 22.6 at M12
(p ¼ 0.0100) (Fig. 2B). In 3 out of the 8 PDQ-8 items signiﬁcant QoL
improvements were observed at M12: item 1 (difﬁculty getting
around in public places: 0.5 ± 1.3, p ¼ 0.0074), item 3 (felt
depressed: 0.4 ± 1.4, p ¼ 0.0372), and item 8 (embarrassed by
having PD: 0.5 ± 1.6, p ¼ 0.0312) while signiﬁcant improvements
in item 7 (painful muscle cramps and pains:0.5 ± 1.3, p¼ 0.0031)
were evident only at M6.
The EQ-5D descriptive score and visual analog scale (VAS)
signiﬁcantly improved up to M6 by þ0.12 ± 0.35 and up to M12
by þ0.17 ± 0.25 (p ¼ 0.0076 and p ¼ 0.0001 respectively; Fig. 2C).Fig. 2. Non-motor symptoms and quality of life Fig. 2: Mean change from baseline to
D1, M6, and M12 of LCIG treatment with PEG tube in A) NMSS total score, B) PDQ-8
total score and C) EQ-5D descriptive score and EQ-5D VAS. Bars are standard devia-
tion. Asterisks represent statistical signiﬁcance (p  0.05) compared to baseline from
paired t-test. Non-Motor Symptoms Scale (NMSS), Parkinson's Disease Questionnaire e
8 item (PDQ-8), EuroQuol- 5 dimensions (EQ-5D), Visual Analog Scale (VAS).
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75 (47.2%) of the 159 patients in the safety analysis population
experienced at least one ADR, and 37 (23.3%) patients experienced
serious ADRs (Table 2A). All ADRs with an incidence 1.5% are
shown in Table 2B. The most common serious ADRs (reported in
more than one patient) were: device dislocation (n ¼ 4), post-
operative wound infection (n ¼ 2), “On” and “Off” phenomenon
(n ¼ 2) and hallucination (n ¼ 2). Eight (5.0%) patients reported an
ADR leading to discontinuation of LCIG (Table 2C). Changes of the
LCIG infusion rate (temporary interruption, increase or reduction of
dose) due to ADRs were recorded in 26 (16.3%) patients. During the
period between start of data collection (June 2010) and data base
snapshot for this interim analysis, 8 patients died; in the in-
vestigators' judgment, none of the deaths were considered to be
related to LCIG.
4. Discussion
This investigation represents the largest cohort of advanced PD
patients treated with LCIG in routine clinical care, involving 75
movement disorder centers in 18 countries. The populationTable 2
Safety and tolerability of LCIG infusion.
A) Summary of Adverse Drug Reactions (ADRs)
Number (%)
of patients
Patients with at least one ADR 75 (47.2%)
Patients with at least one ADR possibly or
probably related to treatment
66 (41.5%)
Patients with at least one serious ADR 37 (23.3%)
Patients with at least one severe ADR 15 (9.4%)
Patients with at least one ADR leading to LCIG discontinuation 8 (5.0%)
Patients with at least one ADR leading to LCIG interruption 14 (8.8%)
Patients with at least one ADR leading to LCIG decrease 8 (5.0%)
Patients with at least one ADR leading to LCIG increase 4 (2.5%)
B) ADRs reported in patients at an incidence 1.5%
Preferred term Number (%) of patients
Weight decreased 9 (5.6%)
Device dislocation 6 (3.8%)
Abdominal pain 5 (3.1%)
Polyneuropathy 5 (3.1%)
Granuloma 4 (2.5%)
Injection site infections 4 (2.5%)
Postoperative wound infection 4 (2.5%)
Device complication 3 (1.9%)
Gastrointestinal stoma complication 3 (1.9%)
Hallucination 3 (1.9%)
C) ADRs leading to study discontinuationa
System/organ class Preferred term Number (%)
of patients
Cardiac disorders Cardiac failure 1 (<1%)
Myocardial infarction 1 (<1%)
General disorders and
administration site
conditions
Device dislocation 1 (<1%)
Device infusion issue 1 (<1%)
Gastrointestinal disorders Nausea 1 (<1%)
Duodenal ulcer 1 (<1%)
Gastro-esophageal reﬂux disease 1 (<1%)
Infections and infestations Postoperative wound infection 1 (<1%)
Psychiatric disorders Psychotic disorder 1 (<1%)
Other Not speciﬁedb 1 (<1%)
A) Overall summary of adverse drug reactions (ADRs) reported during LCIG infusion
with temporary nasoduodenal tube and long-term PEG tube, B) ADRs reported with
an incidence of 1.5% and C) ADRs leading to study discontinuation.
a N ¼ 159 patients in safety analysis, 8 total discontinued due to an ADR. Each
patient discontinuation could be attributed to 1 ADRs.
b Records of treating physician indicated “other” without further speciﬁcation.included in this study represents a cohort of advanced PD patients
with pronouncedmotor ﬂuctuations similar to cohorts described in
other studies [14,15,20] This interim analysis showed marked im-
provements on motor complications as well as several non-motor
symptoms and QoL, with a safety proﬁle consistent with the pub-
lished LCIG data [7,8,13,15,16e18].
Speciﬁcally, there were robust reductions in total daily “Off”
time as recorded via the UPDRS IV item 39. While the original
UPDRS requires the patient to judge the percentage of daily “Off”
time in 25% increments, use of the descriptors for the corre-
sponding item of the MDS-UPDRS provided more detailed ques-
tioning about hours of sleep and wake time reported as daily “Off”
hours [22]. The average reduction of 4.7 h is similar to the 4.0 h
“Off”-time reduction recorded by patient diary in the LCIG arm of
the recent double-blind, double-dummy trial [8].
Patients in the cohort described here also reported signiﬁcant
reductions in daily “On”-time with dyskinesias and dyskinesia
severity both at M6 and M12, which is consistent with previous
open-label reports [16e20]. Interestingly, the reduction of the
severity of dyskinesia was more marked compared to the decrease
in the duration of dyskinesias.
The methodology of this observational study did not allow dif-
ferential assessment of non-troublesome and troublesome dyski-
nesias, but baseline dyskinesia severity was mild to moderate in
this cohort. On average, dyskinesia reduction occurred despite
mean increases in daily levodopa exposure after switching from
oral levodopa treatment to LCIG, consistent with the concept that
there is a therapeutic window in advanced PD and that continuous
delivery seems to be a key factor in the management of motor
ﬂuctuations [8]. The mean LCIG dose appeared to increase from BL
to D1, whichwas associatedwith a decrease in concomitant anti-PD
use, suggesting that LCIG was increased to compensate for tapering
of other medications upon initiation of LCIG. Subsequently, the
mean LCIG dose administered through PEG at D1 remained stable
over 12 months. Stable LCIG doses were also reported in other
studies conducted in medical routine care [14,20] suggesting no
tolerance development in long-term treatment.
We also observed an improvement of both UPDRS parts II and III
of approximately 20% by M12. Other clinical studies with LCIG also
reported signiﬁcant decreases of the UPDRS II and III scores [13,16],
and it is unclear whether UPDRS III improvements primarily reﬂect
continuous delivery and increased effective levodopa dose, or
improved mobility as a consequence of reduced dyskinesia severity
and “Off” time. Both factors may have contributed to these
improvements.
There was a signiﬁcant improvement in total NMSS score (27%
and 29% reduction) at M6 and M12, respectively, which is consis-
tent with the concept that speciﬁc non-motor features can be
ameliorated by optimizing dopaminergic delivery [23]. Indeed,
Storch and colleagues have recently shown that a majority of PD
patients with motor ﬂuctuations report greater prevalence of a
variety of non-motor symptoms when in the “Off” as compared to
the “On” state and also had greater non-motor symptom severity in
the “Off” versus “On” state [24]. Improvement in the NMSS does not
allow us to establish precisely whether this is linked to “Off” time
reduction, but the observation that this was driven by items such as
sleep/fatigue and urinary problems supports sensitivity of these
domains to dopaminergic therapy [12]. Moreover, presence of
sleep/fatigue and urinary problems were also reported in a recent
survey as reason for therapy change by both patients and neurol-
ogists in a large percentage of advanced PD. [25].
Finally, the beneﬁcial effects observed on the key motor and
non-motor outcomes of this interim analysis were also reﬂected by
a marked improvement in quality of life (18% reduction of the PDQ-
8 score) [19e21].
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established safety proﬁle of LCIG over a longer time period. The
level of premature discontinuations reported in this study was
lower than [16] or comparable with other studies [11]. Discontin-
uation of treatment with LCIG due to ADRs was observed in 5.0% of
patients and related mainly to gastrointestinal or device compli-
cations or postoperative wound infection. Complications of LCIG
treatment such as postoperative wound infection, site injection
infection and granuloma were the most common events. Cases of
polyneuropathy were reported in this and also in other studies
[11,20] Neuropathy has been considered as a possible complication
of LCIG infusion however, the etiology remains unclear [26e30]. It
has been suggested that vitamin B12 deﬁciency might be impli-
cated and that vitamin B12 should be supplemented during LCIG
treatment [29]. Physicians should be aware of this possibility and
monitor their patients accordingly [29,30].
Since this investigation is being conducted as an observational
study collecting data recorded during routine medical care, we
consider these outcomes to be close to ‘real world’ clinical practice.
In general, our outcomes are consistent with results generated in
controlled short-term clinical studies. The results reported here
have been derived from a 12-month interim analysis while re-
cordings of clinical outcomes will continue through 24 months in
this large cohort of 375 patients with advanced PD to assess ben-
eﬁts of LCIG infusion over a 2-year period. A limitation of the study
is the potential positive selection bias inherent of this type of study
design over time, which may reﬂect real life practice.
In conclusion, the consistent signiﬁcant and clinically-relevant
improvements over 12 months in motor ﬂuctuations, non-motor
symptoms and QoL at stable LCIG doses and conﬁrmation of the
established safety proﬁle add to the existing evidence of LCIG
treatment in advanced PD patients and suggest consideration of
LCIG as a long-term treatment strategy in patients with advanced
PD.
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